SCHEMBL4936500

SCHEMBL4936500

O=C(O)c1ccc(CNCCc2cc(F)ccc2COc2ccc(C3CCCCC3)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 12/20 0.57
PPARA Q07869 2/20 0.45
NR4A2 P43354 2/20 0.44
MRGPRX4 Q96LA9 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4936414 0.91 FFAR4 (0.53) FFAR4PPARAHRH3
SCHEMBL4650113 0.79 FFAR4 (0.62) FFAR4
SCHEMBL6430135 0.78 FFAR4 (0.53) FFAR4PPARAHRH3
SCHEMBL2885997 0.78 FFAR4 (0.42) FFAR4PPARA
SCHEMBL4651759 0.75 FFAR4 (0.56) FFAR4HRH3
SCHEMBL4650715 0.75 FFAR4 (0.60) FFAR4MRGPRX4HRH3
SCHEMBL4650030 0.73 FFAR4 (0.55) FFAR4MRGPRX4HRH3
SCHEMBL17028567 0.73 FFAR4 (1.00) FFAR4
SCHEMBL4928507 0.72 FFAR4 (0.55) FFAR4MRGPRX4HRH3
SCHEMBL4938902 0.71 FFAR4 (0.51) FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329777-B2 Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis BAYER AKTIENGESELLSCHAFT (DE) 2008-02-12 US disclosed
US-20050288366-A1 Novel aminodicarboxylic acid derivatives BAYER AKTIENGESELLSCHAFT (DE) 2005-12-29 US disclosed
US-6939990-B2 Derivatives of dicarboxylic acid having pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2005-09-06 US disclosed
US-20040110840-A1 Novel derivatives of dicarboxylic acid having pharmaceutical properties BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110840-A1 Novel derivatives of dicarboxylic acid having pharmaceutical properties SDHA, GOT2, MDH2 FFAR4 806/4885PPARA 554/4885NR4A2 3888/4885
US-20050288366-A1 Novel aminodicarboxylic acid derivatives DDC, DAO, AADAT FFAR4 816/4885PPARA 629/4885NR4A2 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.